Accession Number:

AD1083385

Title:

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Descriptive Note:

Journal Article - Open Access

Corporate Author:

Massachusetts Institute of Technology Cambridge United States

Report Date:

2018-07-26

Pagination or Media Count:

19.0

Abstract:

Introduction Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain unexplained by genomic properties. Emerging evidence shows that receptor tyrosine kinase RTK reprogramming is a major alternative process causing targeted drug resistance, separate from genetic alterations. Hence, the contributions of mechanisms leading to this process need to be more rigorously assessed.

Subject Categories:

  • Genetic Engineering and Molecular Biology
  • Medicine and Medical Research
  • Statistics and Probability

Distribution Statement:

APPROVED FOR PUBLIC RELEASE